The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats

Zhao,Juan; Yu,Quan-Xin; Kong,Wei; Gao,Hai-Cheng; Sun,Bo; Xie,Ya-Qin; Ren,Li-Qun

doi:10.3892/etm.2013.1052

June 2013 Volume 5 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June 2013 Volume 5 Issue 6

Full Size Image

Article

The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats

Authors:
- Juan Zhao
- Quan-Xin Yu
- Wei Kong
- Hai-Cheng Gao
- Bo Sun
- Ya-Qin Xie
- Li-Qun Ren
View Affiliations / Copyright

Affiliations: Department of Pathophysiology, Chengde Medical University, Chengde, Hebei 067000, P.R. China, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China
Pages: 1765-1769
|
Published online on: April 9, 2013

https://doi.org/10.3892/etm.2013.1052
Expand metrics +

Abstract

The aim of this study was to explore the use of urantide as an antagonist of the urotensin II (UII) receptor, G protein‑coupled receptor 14 (GPR14), to protect against atherosclerosis (AS) in rats. The AS rat model was induced by an intraperitoneal injection of vitamin D3 (VD3) into rats fed with a high-fat diet for four weeks. Urantide was then injected into the rats. Immunohistochemical staining, serum biochemical assay, reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were used to investigate the expression of UII and its receptor GPR14 in the AS rat model. Four weeks after induction, pathological changes typical of AS were observed in the AS rat model. In the plaques of the aortic tunica intima and tunica media, expression of UII and GPR14 was observed. The protein and gene expression levels of UII and GPR14 in the model group were significantly increased compared with those in the normal group (P<0.01). Urantide ameliorated the pathological changes of AS in the rat model and reduced the gene and protein expression levels of UII and GPR14 (P<0.05 or P<0.01). UII is associated with AS and the UII receptor GPR14-specific antagonist, urantide, demonstrates the ability to protect against AS. Thus, this study provides new insight and experimental theories for the clinical application of urantide to treat AS.

View Figures

View References

1.	Ban Y, Watanabe T, Suguro T, Matsuyama TA, Iso Y, Sakai T, Sato R, Idei T, Nakano Y, Ota H, Miyazaki A, Kato N, Hirano T, Ban Y and Kobayashi Y: Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb. 16:179–187. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Cheriyan J, Burton TJ, Bradley TJ, Wallace SM, Mäki-Petäjä KM, Mackenzie IS, McEniery CM, Brown J and Wilkinson IB: The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. Br J Clin Pharmacol. 68:518–523. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Hassan GS, Douglas SA, Ohlstein EH and Giaid EH: Expression of urotensin-II in human coronary atherosclerosis. Peptides. 26:2464–2472. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Babińska M, Holecki M, Prochaczek F, Owczarek A, Kokocińska D, Chudek J and Więcek A: Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome? Arch Med Sci. 8:449–454. 2012.PubMed/NCBI
5.	You Z, Genest J Jr, Barrette PO, Hafiane A, Behm DJ, D’Orleans-Juste P and Schwertani AG: Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice. Arterioscler Thromb Vasc Biol. 32:1809–1816. 2012. View Article : Google Scholar : PubMed/NCBI
6.	Camarda V, Spagnol M, Song W, Vergura R, Roth AL, Thompson JP, Rowbotham DJ, Guerrini R, Marzola E, Salvadori S, Cavanni P, Regoli D, Douglas SA, Lambert DG and Calò G: In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4–11) (UFP-803). Br J Pharmacol. 147:92–100. 2006.PubMed/NCBI
7.	Camarda V, Song W, Marzola E, Spagnol M, Guerrini R, Salvadori S, Regoli D, Thompson JP, Rowbotham DJ, Behm DJ, Douglas SA, Calo’ G and Lambert DG: Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol. 498:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P and Loirand G: Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-Kinase. Circ Res. 88:1102–1104. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Gao S, Oh YB, Shah A, Park WH, Chung MJ, Lee YH and Kim SH: Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol. 299:H1782–H1789. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N and Douglas SA: Urotensin II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 370:238–250. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Xu S, Wen H and Jiang H: Urotensin II promotes the proliferation of endothelial progenitor cells through p38 and p44/42 MAPK activation. Mol Med Report. 6:197–200. 2012.PubMed/NCBI
12.	Matsusaka S and Wakabayashi I: Enhancement of vascular smooth muscle cell migration by urotensin II. Naunyn Schmiedebergs Arch Pharmacol. 373:381–386. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J and Tang C: Proliferation and antiapoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis. 188:260–264. 2006. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles